Thomas G.
- Country
- France
- Department
- MEDICAL ONCOLOGY
Research Overview
- Phase 3 Study Comparing Rinatabart Sesutecan Versus Investigator's Choice in Patients With Recurrent or Progressive Endometrial Cancer Following Platinum-Based and PD(L)-1 Therapy
- Study of Inavolisib with Trastuzumab and Pertuzumab as Maintenance Therapy in Patients with HER2‑Positive PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer
- De-escalation of endocrine therapy in postmenopausal women with low-risk HR+ HER2- low Luminal A early breast cancer: a single-arm study of omission versus combination therapy
Data & Insights
Has run more than one trial at 325 of 638 partner sites.
Specializations
Breast Cancer Therapeutics
The investigator specializes in treating various forms of breast cancer, with particular emphasis on hormone receptor-positive and HER2-negative disease states.
- Triple Negative Breast Cancer Treatment
- Hormone Therapy Management
- Advanced Metastatic Disease
Research interests include endocrine therapy optimization and treatment strategies for early-stage and metastatic breast cancer.
Targeted Therapies
Focus on developing and implementing precision medicine approaches for breast cancer treatment, including novel therapeutic combinations.
- Immunotherapy Applications
- Anti-HER2 Treatments
- CDK4/6 Inhibitor Therapies
Expertise in evaluating therapeutic response through biomarker analysis and personalized treatment approaches.
Gynecologic Oncology
Conducts research in ovarian cancer treatment, particularly focusing on recurrent disease and maintenance therapy strategies.
- Platinum-Sensitive Ovarian Cancer
- Novel Combination Approaches
- Chemotherapy Optimization
Specializes in developing treatment protocols for advanced gynecologic malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.